Expert Review of Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 18(10), P. 661 - 672
Published: Oct. 2, 2024
Introduction In recent years, significant progress has been made in treatment strategies for intermediate-stage hepatocellular carcinoma (HCC), which is a highly heterogeneous patient population requiring tailored therapies based on tumor characteristics.
Language: Английский
Annals of Surgery Open, Journal Year: 2025, Volume and Issue: 6(1), P. e562 - e562
Published: March 1, 2025
Background: With advancements in drug therapy, local treatments, and evolving concepts, conversion therapy has shown benefits for patients initially diagnosed with unresectable hepatocellular carcinoma (HCC). Over the past 10 years, field accumulated a vast amount of underutilized data, necessitating in-depth bibliometric evaluation. Methods: This cross-sectional retrospective study collected substantial research on published between 2014 2023, adhering to strict search criteria. The primary outcomes were publication volume, citation count, interstudy relationships. Comprehensive analysis was conducted using unsupervised hierarchical clustering, spatiotemporal analysis, regression model, Walktrap algorithm. Results: decade, demonstrated significant progress, an annual growth rate 23.0%. Post-2020, these metrics saw marked increase, reaching 116 publications 1943 citations by 2023. Cluster grouped 244 authors into 17 clusters, highlighting early sustained contributions from Western compared later-emerging Eastern authors. Research characteristics HCC classified 5 2 (Target Therapy Immunotherapy) emerging as new focus. Thematic categorized 4 quadrants, identifying “immune checkpoint inhibitor” “combination therapy” highly relevant rapidly developing themes, while “hepatic arterial infusion chemotherapy” “radioembolization” show high potential future research. Conclusions: highlights key contributors trends provides important predictions directions. To achieve effective HCC, researchers may prioritize immunotherapy locoregional treatments such hepatic chemotherapy or radioembolization.
Language: Английский
Citations
0
BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)
Published: April 3, 2025
This study aimed to evaluate the predictive efficacy of prognostic nutritional index (PNI) in patients with intermediate and advanced hepatocellular carcinoma (HCC) treated a regimen consisting hepatic arterial infusion chemotherapy (HAIC), PD-(L)1 inhibitors, molecular targeted therapies (MTTs). A retrospective analysis was performed on data 88 HCC received triple therapy between January 2020 August 2022 at three medical centers. Univariate multivariable analyses were conducted assess relationship PNI survival outcomes. The median follow-up 11.0 months (IQR: 8.0-17.0). cut-off value 38.6 determined using receiver operating characteristics (ROC) analysis. overall (OS) durations 29.0 8.0 high-PNI (≥ 38.6) low-PNI (≤ groups, respectively (HR = 0.306, 95% CI, 0.170-0.552, P < 0.001), progression-free (PFS) were16.0 6.0 months, 0.521, 0.303-0.896, 0.014). higher complete response rate observed group (17.5% vs. 3.2%, 0.033). univariate revealed that ≥ had an independent influence both OS 0.296; 0.159-0.551, 0.001) PFS 0.560; 0.318-0.987, 0.045). is objective convenient tool can potentially predict prognosis HAIC-based therapy.
Language: Английский
Citations
0
Surgery Today, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 27, 2024
Language: Английский
Citations
2
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15
Published: July 31, 2024
Purpose This study aimed to assess the clinical efficacy and safety of combined approach involving hepatic arterial infusion chemotherapy (HAIC) tyrosine kinase inhibitors (TKIs) for treatment advanced hepatocellular carcinoma (HCC). Patients methods In this multicenter retrospective conducted from January 2020 December 2023, we reviewed HCC patients who were treated either with HAIC alone or a combination TKIs. To address initial disparities between two groups, employed propensity score matching (PSM). Tumor response evaluation was performed following RECIST 1.1 criteria. We compared survival outcomes, including overall (OS), progression-free (PFS), objective rate (ORR), groups. Safety assessments all patients. Results Following eligibility review, 138 underwent TKIs (HT group), while 198 received monotherapy (HA group) met inclusion criteria enrollment in study. After PSM, 107 assigned each group. The HT group exhibited longer median OS (18.0 versus 8.8 months; hazard ratio [HR], 0.52, p < 0.001) HA Median PFS also group, although without statistical significance (6.0 4.7 HR, 0.85, = 0.265). demonstrated higher ORR (41.1% 25.2%; 0.020). No significant differences observed groups incidence adverse events (AEs) grade 3/4 AEs (any grade: 81.2% 78.8% HA, 0.68; 3/4: 18.1% 13.6% 0.29). Importantly, manageable acceptable. Notably, no 5 occurred Conclusion Combination therapy effectively prolonged It represented preferable alternative monotherapy, safety.
Language: Английский
Citations
2
Journal of Hepatocellular Carcinoma, Journal Year: 2024, Volume and Issue: Volume 11, P. 1473 - 1479
Published: July 1, 2024
The combination of sorafenib and hepatic arterial infusion chemotherapy (SoHAIC) has shown to enhance overall survival rates in patients with advanced hepatocellular carcinoma major portal vein tumor thrombosis (HCC-Vp3-4) compared alone. Our objective was evaluate the cost-effectiveness SoHAIC versus for treatment HCC-Vp3-4, taking into account viewpoint Chinese healthcare payers.
Language: Английский
Citations
1
Expert Review of Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 18(10), P. 661 - 672
Published: Oct. 2, 2024
Introduction In recent years, significant progress has been made in treatment strategies for intermediate-stage hepatocellular carcinoma (HCC), which is a highly heterogeneous patient population requiring tailored therapies based on tumor characteristics.
Language: Английский
Citations
0